
Join to view full profile
8881 N Main StDayton, OH 45415
Phone+1 937-293-1622
Fax+1 937-245-6308
Dr. Gross is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Howard Gross is an oncologist based in Dayton, OH, who completed his fellowship in Hematology and Medical Oncology at the University of Cincinnati Medical Center. He has residency training in Internal Medicine from Christ Hospital. Dr. Gross has expertise in cold agglutinin disease and cold autoimmune hemolytic anemia. His research contributions include publications on tumor regression in rectal adenocarcinoma, cancer-related fatigue, and treatments related to breast cancer, with several studies being widely cited. Additionally, he has been involved in diverse clinical trials focused on lung and colorectal cancer, among other areas. In recognition of his work, Dr. Gross received the CMS Meaningful Use Stage 1 Certification in 2012-2013.
Education & Training
University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 1979 - 1980
Christ HospitalResidency, Internal Medicine, 1976 - 1979
University of Cincinnati College of MedicineClass of 1976
Certifications & Licensure
OH State Medical License 1977 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
Clinical Trials
- Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jul 19
Publications & Presentations
PubMed
- Walking dose associated with lower cancer-related fatigue among patients with breast cancer.Lindsey J Mattick, Chin-Shang Li, Po-Ju Lin, Luke J Peppone, Allison Magnuson
Journal of the National Cancer Institute. 2026-05-01 - 3 citationsSouthwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma.Christopher D Lao, James Moon, Vincent T Ma, John P Fruehauf, Lawrence E Flaherty
Cancer. 2025-01-01 - 31 citationsProspective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma.William A Hall, Jiahe Li, Y Nancy You, Marc J Gollub, Joseph R Grajo
Journal of Clinical Oncology. 2023-10-10
Grant Support
- Dayton Clinical Oncology ProgramDAYTON CLINICAL ONCOLOGY PROGRAM2014–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: